Molecular Understanding of Endothelial Cell and Blood Interactions with Bacterial Cellulose: Novel Opportunities for Artificial Blood Vessels by Helen Fink et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Molecular Understanding of Endothelial Cell 
and Blood Interactions with Bacterial Cellulose: 
Novel Opportunities for Artificial Blood Vessels  
Helen Fink1, Anders Sellborn2 and Alexandra Krettek3,4 
1Dept of Chemical and Biological Engineering, Chalmers University of Technology 
2Dept of Surgery, Inst. of Clin. Sciences, Sahlgrenska Acad. at University of Gothenburg 
3Dept of Intern. Med., Inst. of Medicine, Sahlgrenska Acad. at University of Gothenburg 
4Nordic School of Public Health  
Sweden 
1. Introduction 
Cardiovascular disease (CVD) is the main cause of death or invalidism in high-income 
countries today. Moreover, worldwide demographic changes are aiding CVD’s rapid 
progression towards the number one killer in middle- and low-income countries. The World 
Health Organisation estimates that if current trends are allowed to continue, about 20 
million people will die from CVD by 2015. This group of disorders, which affect the heart 
and blood vessels, includes coronary heart disease, cerebrovascular disease and peripherial 
arterial disease, deep vein thrombosis and pulmonary embolism. 
The main cause of these acute life-threatening conditions is atherosclerosis. Atherosclerotic 
plaques and restenosis can result in severe occlusions of peripheral and coronary arteries. 
Current treatments include drug therapy and bypass surgery, and depend on the severity of 
the disease. All treatments require molecular understanding of the processes that govern 
atherosclerosis. This is especially important when introducing artificial graft materials in 
vivo. 
Generally, the first choice for vascular replacement graft material is the patient’s own 
vessels, i.e., autologous vessels. If these are in shortage supply or do not exhibit sufficient 
quality due to, e.g., other diseases or previous surgery, artificial alternatives become 
necessary. Today, clinics use biomaterials such as expanded polytetrafluorethylene (ePTFE) 
and polyethylene terephtalate fibre (Dacron®) as prosthetic grafts for reconstructive 
vascular surgery. However, their performance is dismal in small diameter vessels (>6 mm) 
like coronary arteries and peripheral arteries below the knee, resulting in early thrombosis 
and intimal hyperplasia. Therefore, about 10% of patients with CVD are left untreated due 
to the lack of replacement material for small vessels. 
Considering the large number of patients who need replacement vessels, the substantial 
demand for alternative small-caliber grafts is urgent, driving scientists to search for and 
develop new materials. Recently, this has even led to the use of completely biological 
vessels. However, the growth of such requires months, rendering them unsuitable for acute 
situations such as heart infarction, which demand a substitute vessel immediately. 
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2. What is the ideal vascular graft? 
Several issues demand consideration when constructing a vascular graft: the mechanical 
properties of the graft must resemble those of a native blood vessel, and the graft must be 
biocompatible with its host. One important factor is compliance, i.e., how well the vessel 
withstands pressure from the bloodstream and whether it can maintain systemic pressure in 
the vascular system. Vascular grafts should also be “invisible” to the immune system and 
possess non-thrombogenic properties.  
One interesting option is bacterial cellulose (BC), whose unique properties (strength, good 
integration into host tissue and flexibility that allows production in various shapes and 
sizes) make it an exciting candidate for vascular graft material. The most abundant 
biopolymer on earth, cellulose is insoluble in water and degradable by microbial enzymes. 
Several organisms such as plants, algae and bacteria can produce BC. Some members of the 
bacterial genus Acetobacter, especially Gluconacetobacter xylinum, synthesize and secrete 
cellulose extracellularly. The network structure of cellulose fibrils resembles that of collagen 
in the extracellular matrix (ECM). 
This chapter describes how BC interacts with human endothelial cells (EC) and blood. 
Specifically, we will evaluate whether surface modifications could promote adhesion of EC 
and also whether BC’s thrombogenic properties compare favorably with conventional graft 
materials. These properties are critical because materials intended as vascular grafts must 
satisfy many important features, including blood compatibility, cell interactions and 
mechanical properties. 
3. Tissue engineering of blood vessels 
Tissue engineering is a relatively new scientific discipline that combines cells, engineering 
and materials to improve or replace biological functions. Langer and Vacanti, two pioneers 
in the field, describe tissue engineering as an interdisciplinary area that applies the 
principles of engineering and life sciences to the development of biological substitutes that 
restore, maintain or improve tissue formation (Langer & Vacanti, 1993). 
The basic concept of tissue engineering includes a physical support (3D-scaffold) composed 
of synthetic polymers or natural materials (collagen, elastin or fibrin). This support mimicks 
ECM and initially serves as a scaffold or template on which cells can organize and mature in 
vitro prior to implantation at the appropriate location. 
Initial research in the mid-20th century focused on developing bioinert materials, eliciting a 
minimal host response characterized by passive blood transport and minimal interactions 
with blood and tissues. Although widely available, these industrial materials, including 
Teflon and silicone, were not developed specifically for medical applications. Later, the 
production of completely non-reactive substances became unrealistic. 
Today, other biomaterials are being developed to stimulate reactions between proteins and 
cells at the molecular level in a highly precise and controllable manner. The key concept 
underpinning development of such biomaterials is that the scaffold should contain chemical 
or structural information that mimicks cell-cell communication and controls tissue 
formation, such as growth factors, the adhesion peptide Arg–Gly–Asp (RGD) and other 
molecules that mimic ECM components. RGD is the minimal sequence in basement 
membrane proteins such as fibronectin, fibrinogen and von Willebrand Factor, all required 
for cell adhesion (Pierschbacher & Ruoslahti, 1984). 
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A successful tissue engineered blood vessel must: be biocompatible, i.e., noninflammatory, 
nontoxic, nonimmunogenic and noncarcinogenic; infection-resistant and  nonthrombogenic. 
It also must have appropriate mechanical properties, e.g., tensile strength, burst strength, 
good suture retention and compliance, and possess appropriate vasoactive physiological 
properties, including contraction or relaxation in response to neural or chemical stimuli and 
more. 
The feasibility of constructing and using tissue engineered blood vessels was first 
demonstrated in landmark studies by L’Heureux (L'Heureux et al., 1998) and Niklason 
(Niklason et al., 1999). The vessels, which were produced using different in vitro techniques, 
had very good mechanical properties and functioned well in experimental animals. 
Although in vitro and experimental techniques have been developed since then, no clinical 
implantations have been made until now. 
3.1 Biomaterials/biomaterial scaffolds 
Williams defines biomaterial as any natural or man-made material that comprises the whole 
or part of a living structure or biomedical device that performs, augments, or replaces a 
natural function (Williams, 1999). 
Many different materials have been investigated for biomaterial applications. They can be 
divided into natural materials, i.e., collagen (Weinberg & Bell, 1986; L'Heureux et al., 1998); 
fibrin (Cummings et al., 2004; Kumar & Krishnan, 2002); hyaluronic acid (Remuzzi et al., 
2004; Turner et al., 2004); silk fibroin (Zhang et al., 2009) and BC (Backdahl et al., 2006; 
Klemm et al., 2001; Bodin et al., 2007; Fink et al., 2010)) and synthetic polymers, i.e., 
polyglycolic acid (PGA) (Niklason et al., 1999; McKee et al., 2003), polyethylene 
terephthalate (PET) (Sharefkin et al., 1983; Herring et al., 1984) and ePTFE (Zilla et al., 1987; 
Meinhart et al., 2005). The required properties for biomaterials vary with cell type, 
implantation site and strategy for tissue formation. Common demands for all biomaterials 
include biocompatibility, e.g., avoiding foreign body reactions, capsule formation and 
chronic inflammatory reactions. Additionally, materials intended to be in contact with blood 
require evaluation for thrombogenicity. Mechanical properties are important and depend on 
the target tissue. Since biomaterials used as vascular grafts must withstand blood pressure, 
they must be investigated for burst pressure, compliance, suture strength and fatigue before 
using them as implants. 
A recent and popular approach involves electrospinning different materials to create 
nanofibre constructs. Both electrospun synthetic polymers and native ECM proteins have 
been used for cell seeding to construct vascular grafts (Hashi et al., 2007; Huang et al., 2001; 
Boland et al., 2004; Kenawy el et al., 2003). 
3.2 Materials for vascular grafts 
Jaboulay and Briau performed the first arterial transplantation in 1896, but imperfect 
anastomoses resulted in thrombosis (Jaboulay & Briau, 1896). Since then, more sophisticated 
techniques have been developed. The search for arterial vascular grafts began in 1952, when 
Voorhees discovered Vinyon N (nylon), the first fabric graft (Voorhees et al., 1952). A few 
years later, DeBakey discovered Dacron® in 1958 (Nose, 2008). Today, arterial and even 
especially venous autografts are used routinely in surgery, creating bypasses for patients 
with peripheral or coronary occlusive vascular diseases. However, autograft availability is 
limited, particularly for arteries.  
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Dacron® and ePTFE are still widely used as arterial replacements. Despite their success in 
replacing large diameter (>6 mm) high-flow vessels, these materials show thrombogenicity 
and compliance mismatch in low-flow or small-diameter vessels. Sophisticated techniques 
have been evaluated to enhance patency, including chemical modifications, coatings and 
seeding of the surface with different cells. In contrast to natural materials, synthetics often 
lack adhesion sites. Although passive materials can reproduce sufficient physiological 
mechanical strength, proper metabolic function and cellular signalling requires intact 
cellular machinery. 
BC is an attractive material for biomaterial applications. Its structure resembles that of 
collagen, the component in arteries and veins that gives the blood vessel its strength. BC’s 
manufacturing process allows versatility in shape and size, including tubes. Studies have 
shown successful growth of cardiac rat-derived myocytes and fibroblasts (Entcheva et al., 
2004), rat-derived hepatocytes (Kino et al., 1998; Yang et al., 1994) and osteoprogenitor cells 
(Takata et al., 2001) from mice on cellulose-based materials. However, these matrices are 
based not on natural cellulose but rather on derivatives such as cellulose acetate and 
regenerative cellulose. 
Although BC is biocompatible, it generally does not promote cell growth (Watanabe et al., 
1993a). Thus, BC must be modified to support EC adherence. Modification of wet state BC is 
challenging because fibre structure and strength must be maintained. This is especially 
important for vascular grafts, which must withstand blood pressure. 
4. Different approaches to engineered blood vessels  
4.1 Collagen-based blood vessel model  
Weinberg and colleagues developed a collagen-based blood vessel model (Weinberg et al., 
1986). Improvement of the construct’s mechanical properties is ongoing due to poor 
mechanical integrity. 
4.2 Cell self-assembly model  
The cell self-assembly model is made using intact layers of human vascular cells grown to 
overconfluence to form visible sheets of cells and ECM (L’Heureux et al., 1993, 1998).  
A sheet of smooth muscle cells (SMCs) is rolled around a mandrel to form the medial layer. 
Similarly, a sheet of fibroblasts is rolled over the SMC sheet media, forming an adventitial 
layer. Finally, ECs seeded onto the lumen of the matured vessel form a confluent monolayer. 
These constructs withstood more than 2000 mmHg pressure before bursting. 
4.3 Cell-seeded polymeric scaffold–hybrid graft  
This graft was developed by Niklason (Niklason et al., 1999). Vascular cells were seeded into a 
biodegradable scaffold (PGA) and cultured for 8 weeks under pulsatile radial stress (165 beats 
per minute and 5% radial strain). ECs seeded onto the lumen of the construct formed a 
confluent monolayer. Cultured under pulsatile conditions, the histological structure of the 
constructs resembled that of native arteries. Due to high collagen content, the constructs had a 
burst pressure greater than 2000 mmHg and they could contract. In vivo studies of tissue 
engineered blood vessels in Yucatan miniature pigs were promising. 
With degradable material such as PGA, it is critical to ensure adequate strength of ECM 
(collagen, elastin) produced by the vascular cells. Degradation products may be toxic to the 
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cells. Non-degradable scaffolds offer durable support, but tissue acceptance is mandatory. 
Ideally, the scaffold should be compliant, similar to native vessels.  
4.4 Acellularized construct  
A rolled small intestinal submucosa (SIS) has been used as a small diameter vascular graft. 
A cell-free, 100-µm-thick collagen layer derived from small intestine, SIS is compliant, 
making it an interesting candidate for vascular implantation and requiring investigation 
(Roeder et al., 1999, Huynh et al., 1999).  
4.5 Artificial artery generated in the peritoneal cavity 
In the peritoneal cavity, artificial arteries are generated on silastic tubes. The arteries are 
lined by nonthrombogenic, mesothelial (endothelial-like) cells. The feasibility of this 
approach in humans is a matter of debate. 
5. Bacterial synthesized cellulose as biomaterial 
Cellulose, the most abundant biopolymer on earth, is insoluble in water and degradable by 
microbial enzymes. Several organisms, e.g., plants, algae and bacteria can produce cellulose, 
and the bacteria Gluconacetobacter xylinum can synthesize and secret cellulose extracellularly 
(Brown et al., 1976). BC is composed of linear nanosized fibrils of D-glucose molecules (Ross 
et al., 1991). The network structure of cellulose fibrils resembles that of collagen in the ECM 
of native connective tissue (Fig. 1) (Backdahl et al., 2006). 
 
  
Fig. 1. SEM images of (A) collagen and (B) BC reprinted with permission from Backdahl et 
al., 2006. Copyright Elsevier 2006. 
Although BC is not a hydrogel in the true sense of the meaning, it is often referred to as 
such because of its high water content, insolubility in water and highly hydrophilic 
nature. Since BC consists of a highly entangled network of fibrils, it also provides strong 
mechanical properties that ensure the ability of tissue engineered blood vessels to 
withstand mechanical forces and prevent rupture. BC can be designed and shaped into 
three dimensional structures such as tubes or sheets (Backdahl et al., 2006). A major 
advantage of using BC rather than cellulose produced by any other organism is that BC is 
BA
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completely free of biogenic compounds such as lignin, pectin and arabinan found in, e.g., 
plant cellulose. During the production process, it is also possible to modify several other 
properties including pore size, surface properties and layering of the material (Backdahl 
et al., 2008). 
BC is used in various areas including food matrix (nata de coco), dietary fibres, acoustic or 
filter membranes and ultra-strength paper. In addition, BC has been suggested as a potential 
material for tissue engineering in several areas, e.g., as scaffold for tissue engineering of 
cartilage, blood vessels (BASYC) and successful treatment of second and third degree 
burns, stomach ulcers and other situations that require a temporary skin substitute (Biofill, 
Gengiflex, XCell) or to recover periodontal tissue (Gengiflex) (Czaja et al., 2006; Svensson 
et al., 2005; Fontana et al., 1990). 
5.1 Structure and morphology 
Beginning with the water-soluble monosaccharide D-glucose, cellulose synthesis is 
produced extracellularly as pellicles at the air/liquid interface. Glucan chains of BC are 
extruded from several enzyme complexes and aggregated by van der Waals forces to form 
sub-fibrils, approximately 1.5 nm wide. BC sub-fibrils crystallise into microfibrils and then 
into bundles, which form a dense reticulated structure stabilized by hydrogen bonding. In 
culture medium, the bundles assemble into ribbons, forming a network of cellulose. This 
network of cellulose nanofibrils provides BC with high mechanical strength and a water 
retention capacity of about 99% (Iguchi et al., 2000). 
The macroscopic morphology of BC varies with different culture conditions. In static 
conditions, BC accumulates on the surface of nutrient-rich culture medium, at the oxygen-
rich air-liquid interface. Statically cultured BC has lower crystallinity than BC fermented 
during agitation. 
Our molecular studies on EC-blood interactions with BC used BC synthesized by 
Gluconacetobacter xylinum (ATCC 1700178, American Type Culture Collection). Cellulose 
tubes were grown in corn steep liquid media at 30C for 7 days. The cellulose was then 
purified by boiling, first in 0.1 M NaOH at 60C for 4h and then in Millipore water. 
Finally, the cellulose was sterilised by autoclaving for 20 minutes. Due to the production 
process, BC consists of two distinctly different layers: one side has a compact network of 
fibrils with few if any pores, and the other side has a porous network structure. A density 
gradient arises between the sides. 
5.2 Mechanical properties 
The optimal scaffold is a biocompatible biomaterial that provides proper mechanical and 
physical properties, thus promoting cell adhesion and tissue formation. Prior to 
implantation into animals, BC tubes undergo extensive mechanical testing (burst strength, 
compliance and tensile strength). Films or sheets of BC show remarkable mechanical 
strength, due to high crystallinity, high planar orientation of the ribbons, ultrafine structure 
and a complex network (Iguchi et al., 2000). The mechanical properties of BC tubes are 
similar to those of pig carotid arteries (Backdahl et al., 2006). BC’s compliance curve 
resembles that of a native artery more than any other synthetic material on the market, 
which is advantageous. Material density can be altered by varying the culture conditions or 
by post-culture modifications. 
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5.3 Biocompatibility 
Integration of a material with the host tissue is essential for the success of tissue engineered 
blood vessels. According to Williams, the biocompatibility of a material is defined as “the 
ability of a material to perform with an appropriate host response in a specific application” 
(Williams, 1999). Therefore, an appropriate host response would involve a biomaterial that 
induces a very low inflammatory and foreign body response in the host tissue. 
A study by Helenius et al. showed that BC is well integrated into the host tissue and does 
not induce inflammatory or foreign body responses (Helenius et al., 2006). They implanted 
BC pieces subcutaneously in rats and explanted them after 1, 4 and 12 weeks. Incorporation 
of the implant in the host tissue made it difficult to distinguish a clear interface between the 
implant and the host tissue (Helenius et al., 2006). These results are supported by another in 
vivo study, where BC tubes were implanted into the carotid arteries in pigs (Wippermann et 
al., 2009). Therefore, BC clearly has good biocompatibility and shows promising potential as 
scaffold material. 
5.4 Surface modification  
One challenge in the field of vascular grafts involves promoting EC attachment and 
spreading, since many biomaterials similar to BC exhibit limited support for cellular 
adhesion (Watanabe et al., 1993b). Over the years, many strategies have been developed to 
modify material surfaces.  
To optimize cell-biomaterial interactions, manufacturers coat synthetic scaffolds with cell 
adhesive proteins such as collagen, fibronectin or laminin (Seeger & Klingman, 1988; 
Kaehler et al., 1989). However, varying protein composition results in a biofilm with passive 
protein adsorption, and that composition can modify over time (Vroman, 1987). 
Additionally, protein adsorption to BC is very low.  
Much attention has focused on cell adhesion peptide RGD and its derivatives as possible 
alternative for stimulating reproducible and predictable cell adhesion (D'Souza et al., 1991; 
Hersel et al., 2003; Walluscheck et al., 1996; Gabriel et al., 2006). Most RGD modifications occur 
via covalent binding to the material (Massia & Hubbell, 1990). Although cellulose contains 
reactive hydroxyl groups that can be chemically modified, these very same hydroxyl groups 
participate in hydrogen bonding, which holds the cellulose fibre network together. Disruption 
of these bonds associates with loss of fibre ultrastructure (Sassi & Chanzy, 1995; Sassi et al., 
2000). Dry films of BC have been modified with carboxymethyl and acetyl groups (Kim et al., 
2002). However, surface modifications to wet state BC remain incompletely understood. Thus, 
modification of a BC hydrogel is especially challenging, since solvent exchange and cellulose 
modification typically destroy the hydrogel morphology. 
Modification of a BC hydrogel is especially challenging because solvent exchange and 
cellulose modification typically destroy hydrogel morphology. Thus far, most modifications 
have been performed on dried BC. Consequently, a new method is needed to increase cell 
attachment without altering the structure of the BC network. 
5.4.1 Xyloglucan 
Xyloglucan (XG), the most abundant hemicellulose, is present in the primary wall of many 
plants. In contrast to cellulose, XG is water-soluble and interacts strongly with cellulose fibres 
(Hanus & Mazeau, 2006). We have taken advantage of these properties, which provide an 
elegant means of introducing cell adhesion peptide RGD with XG as a carrier molecule to BC. 
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BC and cotton linters, as reference material, were modified with XG and XG bearing a GRGDS 
pentapeptide (Bodin et al., 2007). Compared with organic solvents, modification in the water 
phase was clearly advantageous for preserving the morphology, as observed with SEM (Fig. 2). 
XG adsorption increased the wettability only to a minor extent, possibly explaining the 
decreased or undetectable adsorption of adhesive proteins shown by QCM-D. QCM-D studies 
further revealed that fibrinogen antibodies do not bind to BC, leading to the conclusion that 
cell enhancement would result from the presence of RGD epitopes, not from unspecific protein 
adsorption, e.g., fibronectin, from the cell culture medium. XG also enhances hepatocyte 
adhesion (Seo et al., 2004), and modification of BC with XG does not adversely affect ECs. 
5.4.1.1 Increased cell spreading and adhesion on XGD-modified BC 
XG-RGD-modification increased cell adhesion by 20%, and also increased the metabolism of 
seeded ECs as compared with unmodified BC. In contrast, the proliferation rate was less 
affected, presumably due to biological variation between cell donors. Our results (Fink et al., 
2011a) concur with studies on RGD-grafted regenerated cellulose, which showed that an 
adhesion peptide enhances adhesion by approximately 20% (Bartouilh de Taillac et al., 
2004). Another study showed that cellulose binding proteins bound to different adhesion 
peptides improve adhesion and spreading of human microvascular cells to cellulose 
(Andrade et al., 2010). In our study, the absence of serum negatively influenced cell 
adhesion on unmodified BC but did not act similarly in modified BC, further indicating that 
increased adhesion is peptide specific. 
 
 
Fig. 2. SEM micrograph of BC morphology of (A) cotton linter, (B) unmodified BC, (C) XG-
RGD modified BC and (D) acetone treated BC. Reprinted with permission from Bodin et al., 
2007. Copyright American Chemical Society 2007. 
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Initial cell attachment is crucial to subsequent behaviour such as spreading, proliferation 
and cell differentiation on substrates. The extent of cell spreading is an important parameter 
for the biocompatibility of materials. EC adhesion to the ECM proteins is normally followed 
by cell spreading, a process in which cells reorganize the f-actin cytoskeleton, resulting in 
flattening and spreading of the cell. These polymerised actin filaments attach the cells to the 
substrate via focal adhesions. Cells grown on RGD-modified BC spread out, displaying a 
well-organized actin cytoskeleton with prominent f-actin fibres. They also grow in clusters, 
which we believe is a step towards achieving a confluent monolayer.  
6. Endothelial cells as cellular source for graft lining 
The endothelium is composed of a monolayer of squamous epithelial cells that line the 
inside of blood vessels in a confluent layer, with a total area of 350-1000 m2 and a weight of 
0.5-1.5 kg (Pries et al., 2000; Jaffe, 1987). The morphology of these cells is flat, resembling a 
cobblestone pattern. This morphology is essential to maintaining good blood flow without 
turbulence. ECs function not only as a physiological barrier, separating the blood from 
surrounding tissues, but also as a dynamic layer of cells that displays antithrombotic 
properties in its resting state. This is achieved by physically preventing elements in the 
blood from contacting prothrombotic elements in the subendothelium and by active 
synthesis of various mediators. Endothelial functions help maintain blood vessel function. 
The endothelium upholds delicate balances in the vasculature, i.e., 
vasoconstriction/vasodilatation, anticoagulant/procoagulant properties, blood cell 
adherence/nonadherence and growth promotion/inhibition. It regulates vascular tone, 
maintains hemostasis, controls vascular structure and mediates inflammatory and 
immunological responses. 
The endothelium responds to inflammatory conditions by regulating its own permeability 
and releasing a variety of substances. It mediates inflammation with pro-inflammatory 
mediators including cytokines such as the interleukins (IL) (e.g., IL-1, IL-6, IL-8), platelet-
activating factor (PAF) and also by expressing endothelial cell leukocyte adhesion molecule-
1 (ELAM-1) and intercellular adhesion molecule 1 (ICAM-1), inflammatory mediators that 
control the interaction between EC and circulating blood cells and leukocytes, leading to 
extravasation of leukocytes. 
During an inflammatory response, adhesion molecule P-selectin is expressed on ECs after 
exposure to leukotrine B4 or histamine, which are produced by mast cells. Tumor necrosis 
factor alpha (TNF-) and lipopolysaccharides (LPS) induce P-selectin expression and the 
synthesis of E-selectin, another selectin that appears a few hours after the inflammatory 
process begins. Because the interactions between these selectins and their corresponding 
glycoprotein ligands (sialyl-Lewisx moiety) on leukocytes are relatively weak and reversible, 
leukocytes are unable to attach firmly to the endothelium. Instead, they “roll” along the 
surface of the vessel wall. The interactions are enhanced as other integrins are induced on 
the endothelium.  
Leukocyte integrins LFA-1 and Mac-1 normally adhere only weakly to leukocytes. On the 
other hand, IL-8 and other chemokines bound to the endothelial surface trigger a 
conformational change in LFA-1 and Mac-1 on the rolling leukocytes, increasing 
adhesiveness and consequently firmly anchoring the leukocytes to the endothelium. Rolling 
is arrested and the leukocytes squeeze between the ECs into the subendothelial tissue, a 
process known as diapedesis. 
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6.1 Angiogenesis and vessel remodeling 
ECs regulate vessel structure by producing both growth promoting and growth inhibiting 
factors. SMC growth is stimulated by platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), transforming growth factor alpha (TGF-), endothelin and angiotensin 
II. Growth is inhibited by nitric oxide (NO), prostacylin (PGI2), some FGFs, insulin-like 
growth factor 1 (IGF-1) and thrombospondin.  
Angiogenesis is regulated by a variety of growth factors. Hypoxia and inflammatory 
cytokines such as FGF increase vascular endothelial growth factor-A (VEGF-A) levels 
through autocrine and paracrine mechanisms. VEGF-A, an endothelial-specific growth 
factor that consists of a heparin-binding homodimer, is a major regulator of EC function 
and angiogenesis. VEGF-A activates several EC functions, e.g., proliferation, migration 
and NO-release, processes that participate importantly in new blood vessel formation. 
VEGF-A also increases vessel wall permeability. Both VEGF and FGF induce EC 
production of proteases such as matrix metalloproteinases (MMPs) and plasminogen 
activator (PA). At least twenty MMPs participate in angiogenesis (Kroll & Waltenberger, 
2000; Lamalice et al., 2007). 
Proteases digest the basement membrane, allowing ECs to invade surrounding tissue, where 
they proliferate and migrate to form a sprout. The sprout elongates and the ECs differentiate 
to form a lumen. ECs in the newly formed vessel produce PDGF-BB, which attracts mural 
cells (pericytes to capillaries/SMC to larger arteries and veins) and stabilises the vessel. 
Expressed on ECs, heparin sulphate proteoglycans and their glycosaminoglycans (GAG) 
side-chains play an important role in angiogenesis because they bind circulating growth 
factors like VEGF (Kroll & Waltenberger, 2000). 
6.2 Regulation of vascular tone 
ECs regulate vessel tone and, consequently, local blood flow by managing the 
communication between the blood and the underlying SMCs, and by releasing substances 
that influence SMCs to relax or contract. In addition, ECs synthesise both vasodilating and 
vasoconstricting agents. 
Vasodilatation is mediated through PGI2 and (NO/endothelium-derived relaxing factor 
(EDRF) and endothelium-derived hyperpolarizing factor (EDHF), where NO plays a central 
role. Vasoconstricting agents released by ECs include endothelin, angiotensin II and 
thromboxane A2 (TXA2). 
Shear stress, bradykinin, thrombin, serotonin and various drugs stimulate ECs to release 
prostacyklin, thus stimulating adenylate cyclase, which increases cyclic adenosine 
monophosphate (cAMP) in SMCs. NO is synthesized from L-arginine by NO synthase and 
diffuses to SMCs, where it activates guanylate cyclase to produce cyclic guanosine 
monophosphate (cGMP). This leads to decreased intracellular calcium and muscle 
relaxation. Sensing mechanical changes in the environment, f-actin mediates mechanical 
induction of NO, leading to signal transduction into the cell.  
The eNOS gene contains a shear stress regulatory element (SSRE) that increases or decreases 
eNOS activity (Balligand et al., 2009). Acetylcholine stimulation of M1 muscarinic receptors 
releases endothelium-derived hyperpolarizing factor (EDHF), changing membrane potential 
(Pagliaro et al., 2000). Endothelin consists of three isoforms, ET-1, ET-2 and ET-3. ECs 
produce endothelin-1, the most potent mediator of vasoconstriction. Two endothelin 
receptors are found in the vasculature: ETA on SMCs and ETB on ECs. Binding of endothelin-
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1 to the ETA-receptor results in signal transduction and smooth muscle relaxation. On the 
other hand, activation of ETB on ECs stimulates NO and PGI2 production. In contrast, 
angotensin II is a much weaker vasoconstrictor. Renin cleaves angiotensinogen to 
angiotensin I, which is then converted to angiotensin by endothelial angiotensin-converting 
enzyme (ACE) (Nordt & Bode, 2000). 
7. Blood compatibility of biomaterials is a challenge 
A nonthrombogenic surface is the key to a successful vascular graft. Non-thrombogenicity 
can be achieved by various surface modifications. Since ECs could provide a 
nonthrombogenic surface, intense investigation has focussed on endothelialisation in this 
context. In our studies, we used ECs passage 4 from non-diseased human saphenous veins, 
by-products of coronary bypass surgery.  
The thrombogenicity of a biomaterial is an essential factor for any material that will be in 
contact with blood. Although the thrombogenic property of cellulose has been extensively 
researched as it has been used for haemodialysis membranes (Fushimi et al., 1998; Mao et 
al., 2004), the thrombogenicity of BC remains undetermined because it is a relatively new 
material for vessel grafts. Therefore, one of our studies focussed on delineating the blood 
compatibility of BC in comparison with ePTFE and PET vascular grafts, which are both used 
clinically as graft material (Fink et al., 2011b). 
The endothelium’s most important function in relation to biomaterials is hemostatic control. 
Under normal physiological conditions, ECs express thrombo-resistant molecules, but they 
must be able to switch to a procoagulant state upon injury to initiate coagulation and clot 
formation. Since blood is transported under high pressure, minimization of blood loss 
requires a rapid response. Some molecules are continuously secreted by ECs while others 
are only produced upon stimulation. Molecules can be expressed on the surface or secreted 
into the blood stream. The different endothelial anti- and procoagulant factors are discussed 
below in their biological context. 
7.1 Primary hemostasis – Platelet adhesion, activation and aggregation 
Prostacylin I2 (PGI2), nitric oxide (NO) and adenosine diphosphatase (ADPase) suppress 
platelet activation, aggregation and platelet-wall-interaction. Both NO and PGI2 are 
secreted and act in a paracrine manner, whereas ADPase is expressed on the EC surface. 
Platelet inhibition by PGI2 is mediated through a guanosine nucleotide binding receptor. 
This receptor-mediated signal transduction increases cAMP levels and inhibits platelet 
activation and the release of proaggregatory compounds such as TXA2 (Moncada, 1982). 
PGI2 production is stimulated by diverse agonists such as thrombin, histamine and 
bradykinin, and synthesised via arachidonic acid (AA) and prostaglandin (PGG2) (Wu, 
1995).  
ECs produce EDRFs, which are responsible for acetylcholine-induced vasorelaxation. The 
most important EDRF is NO, which synthesises nitric oxide synthase (NOS) by converting 
L-arginine. NO is a small molecule, so it diffuses easily. When NO enters platelets, it inhibits 
their adhesion and activation via guanylyl cyclise (Radomski et al., 1987c). PGI2 and NO 
have synergistic effects on inhibition of platelet adhesion, activation and aggregation and 
also reverse platelet aggregation (Radomski et al., 1987a; b) 
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7.2 Secondary hemostasis – Coagulation 
The endothelium physically separates coagulation factor VIIa from tissue factor (TF) and 
prevents platelet exposure to collagen and von Willebrandt factor (vWF) (Fig. 3). 
Thrombomodulin (TM) is expressed on the surface of ECs. Thrombin binds to TM, thereby 
undergoing a conformational change that results in enhanced affinity for protein C. 
Thrombin is the only enzyme capable of activating protein C. Activated protein C cleaves 
and inactivates clotting factors Va and VIIIa (Esmon, 1993). The thrombin-TM complex, 
effectively removes thrombin from the blood and internalises it, leading to its degradation. 
The TM molecule can also bind FXa, thus inhibiting prothrombin activation (Thompson & 
Salem, 1986). Protein S, also synthesised by ECs, binds to the endothelial surface and protein 
Ca to form a complex, thus enhancing FVa and FVIIIa inhibition (Fig.  3).  
The endothelium expresses heparin sulphate proteoglycans with anticoagulant activity on 
its surface. Heparin is a cofactor for antithrombin III, a plasma protein present that can 
inhibit thrombin, IXa, FXa and XIIa. The complex binding of thrombin to antithrombin III 
occurs slowly. This process is accelerated by the interaction with heparin, which has many 
binding sites for antithrombin, and serves to localise and increase its activity more than a 
thousand-fold. The ┚-isoform of antithrombin is more highly effective than the -isoform. 
Moreover, the -isoformis effectively inhibits thrombin-induced SMC proliferation 
(Swedenborg, 1998). Synthesised in the liver and also by ECs, tissue factor pathway inhibitor 
(TFPI) forms a complex with Xa and inactivates the VIIa-tissue factor complex by binding to 
it. 
 
 
Fig. 3. Schematic illustration of the regulation of coagulation by ECs. 
7.2.1 Procoagulation factor 
The endothelium also participates importantly in the initiation of coagulation, which arrests 
bleeding. It expresses a variety of procoagulant factors, including vWF, coagulation factors 
V and VII, TF and high molecular weight kininogen (HMWK). 
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ECs synthesise vWF, a platelet adhesion molecule that secretes following stimulation by 
thrombin, and stores it in vesicles (Weibel-Palade bodies). vWF possesses binding sites for 
coagulation factor VIII, collagen (exposed after injury) and platelets (GPIb- XI-V), and acts 
as a bridging molecule in platelet aggregation and activation (Ruggeri, 1994). Importantly, 
the absence of vWF leads to severe bleeding disorders. 
ECs also secrete TF, which is found mainly in the subendothelium at sites not normally 
exposed to the bloodstream. The basal production of TF is low in comparison with the 
underlying SMCs and fibroblasts, but it can increase 10- to 40-fold upon stimulation. In 
addition, ECs have binding sites for factor VII, IX, IXa, X and Xa. Binding to factor IXa 
inhibits EC decay in the presence of factors VIII and X, which provide an additional 
feedback mechanism for cell-bound procoagulant activity (Jaffe, 1987; Vane et al., 1990). 
7.2.2 Fibrinolysis 
The endothelium also helps regulated fibrinolysis (Fig. 3). The degradation of fibrin requires 
plasmin. Plasminogen binds to the cell surface and facilitates plasmin conversion by two 
PAs, tissue type plasminogen activator (tPA) and urokinase (uPA) (van Hinsbergh). 
Physiologically, the most important PA in vascular fibrinolysis is tPA. Indeed, tPA enhances 
the conversion of plasminogen 100-fold when it binds to fibrin. The release of tPA is either 
constitutively or pathway-mediated. Thrombin, FVa, bradykinin, PAF and shear stress all 
induce the synthesis and release of tPA from ECs (Emeis, 1992; Giles et al., 1990; Brown et 
al., 1999). When tPA binds to the EC surface, it is protected from degradation by the two PA 
inhibitors (PAI), PAI-1 and PAI-2, which are also released by ECs. PAI-1 requires 
vitronectin, present in ECM, to maintain its activity; it is the main inhibitor to tPA. 
Recombinant t-PA (rt-PA) is the most frequently used substance for inducing thrombolysis 
by pharmacological means (Noble et al., 1995; Bennett et al., 1991). 
7.2.3 Biomaterial-induced coagulation 
Evaluation of coagulation induced by biomaterials is mostly studied in terms of platelet 
adhesion, partial thromboplastin time (PTT), protein adsorption by QCM-D or ellipsometry 
(Liu et al., 2009; Mao et al., 2004;van Oeveren et al., 2002; Keuren et al., 2003). The QCM-D 
method is surface-sensitive, but the distance from the surface to where measurement is 
possible is limited. Currently, it is not possible to attach BC to quartz crystals. Therefore, 
cellulose other than BC must be used. However, this material could be used for QCM-D 
measurements as a model surface, complementing other studies. Because ellipsometry is an 
optical method, it is not possible to use native BC for this assay either. Automated calibrated 
thrombin generation is very sensitive and has become a widespread method for quantitative 
analysis of coagulation kinetics in blood plasma (van Oeveren et al., 2002; Gerotziafas et al., 
2005; Hemker et al., 2003). Thrombin generation is also considered the most sensitive 
method to assay thrombogenicity. 
Since BC is used in a wet state, finding appropriate analysis techniques has been challenging. 
To our knowledge, ours is the first study to investigate the thrombogenic properties of BC 
compared with other graft materials (Fink et al., 2011b). We also developed a modified 
automated calibrated thrombin generation assay (Fink et al., 2010). This makes it possible to 
follow thrombin generation, in the presence of a material, in real time rather than using an 
endpoint assay. Our assay has led to new insights into the kinetics of thrombin generation 
induced by a material surface, which otherwise would have been missed. 
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Most methods that study the coagulation process measure coagulation in the bulk without 
regards to where it began or the kinetics describing the propagation from the initiation 
point. Our method (Fink et al., 2011b) makes it possible to visualize the exact initiation point 
of coagulation and determine how coagulation propagates (Kantlehner et al., 2000). The 
captured images are used to calculate the coagulation time of the plasma at the surface 
(surface coagulation time) and into the bulk (propagation). Such factors are highly relevant 
to the study of material interactions with blood. 
 
 
Fig. 4. Thrombogram generated from thrombin generation assay displaying lagtime, time to 
peak (ttPeak), peak and endogenous thrombin potential (ETP). 
We measured the levels of thrombin and factor XIIa using calibrated automated 
thrombography, which displays the concentration of thrombin and factor XIIa, respectively, 
in clotting plasma with or without platelets (platelet-rich plasma/platelet-free plasma, 
PRP/PFP). The splitting of a fluorogenic substrate is monitored for either thrombin or factor 
XIIa and compared with a known thrombin or factor XIIa activity, respectively, in a parallel 
non-clotting sample. To evaluate thrombin and factor XIIa generation exclusively induced 
by the biomaterial surfaces, we fixed material samples with heparinised O-rings and 
analysed them by calculating the average rate of fluorescence increase over a period of 60 
min. 
7.2.3.1 Biomaterial induced coagulation of biological cellulose 
We compared biomaterial-induced coagulation of BC with clinically used graft materials, 
i.e., ePTFE and PET. In addition, we visualised coagulation propagation at the material 
surfaces and into the plasma bulk.  
Thrombin generation experiments revealed dramatic differences between the tested 
materials (Fink et al., 2010). Both ePTFE and BC generate longer lagtimes and time to Peak 
(ttPeak) values than PET (Fig. 4). Furthermore, BC generates the lowest ‘Peak’, indicating a 
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slower coagulation process at the surface. These results are also supported by the 
measurements of factor XIIa generation and analysis of surface coagulation times, where BC 
had the lowest FIIa generation and slowest propagation of coagulation into the bulk (Fig. 5). 
Compared with PET, thrombin generation in the whole blood Chandler-Loop system 
depicted the same response, yielding decreased accumulation of thrombin-antithrombin III 
complex (TAT) on both BC and ePTFE. Since the measurements are performed after one 
hour and not continuously, the difference in coagulation speed cannot be observed. On the 
other hand, this assay is performed in whole blood during flow conditions that more closely 
resemble an in vivo situation compared to measurements in platelet-free plasma during 
static conditions. It is interesting and promising that these two systems show similar results.  
 
 
Fig. 5. Representative time-lapse images from a comparative experiment in the imaging of 
coagulation setup. Graft material samples are attached along the left wall in the images. The 
colour represents the density of the formed fibrin network (Courtesy of Lars Faxälv, PhD). 
Hypothetically, the slower coagulation process on BC (Fig. 5) could be an advantage when 
blood contacts biomaterial applications, because it would provide time for the blood flow to 
divert and dilute activated coagulation products. The whole blood model also shows that 4 
mm BC tubes perform well regarding anti-thrombogenic properties and perform better 
compared with ePTFE than 6 mm tubes. Measurements of thrombin generation correlate 
very well with the XIIa generation assay and visualisation of propagation. Together these 
methods potentially could provide fast screening methods for evaluating the 
thrombogenicity of biomaterials.  
The amount of TAT generated depends on blood velocity (e.g., shear rate) in the loop 
system. Higher velocities associate with increased TAT generation. Shear rates are higher in 
the 4 mm loop system compared with the 6 mm system, and the narrower material also 
exhibits greater coagulation activation. Interestingly, however, platelet consumption does 
not increase, suggesting platelet activation. The amount of TAT generated on ePTFE 
increased 18-fold on 4 mm tubes as compared with 6 mm tubes, but we detected only a 3-
fold increase for BC tubes. In comparison with the other tested materials, the platelet 
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consumption of BC is remarkably low, especially compared with heparinised polyvinyl 
chloride (PVC), which is known to have low thrombogenic properties (Johnell et al., 2005). 
In addition, cellulose showed no visible sign of clotting following one hour of incubation 
with whole blood containing only small amounts of soluble heparin. 
7.3 Complement system  
The immune complement system (CS) is part of the innate immune system. Its main task is 
to protect the body from pathogenic agents like bacteria, viruses and fungi. On contact with 
a foreign surface, e.g., a bacterial surface, the CS activates in a cascade that either destroys 
the bacterial surface or releases bioactive degradation products, or both, causing 
inflammatory reactions in the surrounding tissue.  
Consisting of more than 30 different cell-bound and soluble proteins that circulate as 
inactive zymogens under nonpathological conditions, the immune CS is present in blood 
and serum. Its most important factor is complement factor 3 (C3). Cleavage of C3 by C3 
convertase creates C3a and C3b, causing a cascade of further cleavage and activation events. 
Three different pathways lead to the creation of C3 convertase: the classical pathway, the 
alternative pathway and the mannose-binding lectin pathway. The classical complement 
pathway typically requires antibodies for activation, whereas the alternative and lectin 
pathways can be activated by C3 hydrolysis or antigens without the presence of antibody. 
7.3.1 Classical pathway 
Classical convertase is initiated when antibodies bind to a surface such as a bacterium. 
When factor C1 binds to an antibody, it cleaves is cleaved and binds to additional factors  
forming the classical convertase (C4b2a) (Kinoshita, 1991). 
7.3.2 Alternative pathway 
The alternative pathway is triggered by either spontaneous C3 hydrolysis, which forms C3a 
and C3b, or covalent binding of C3b from the classical and lectin pathways to a surface. The 
C3b molecule is capable of covalently binding to a pathogenic membrane surface in its 
vicinity. If there is no pathogen in the blood, the C3a and C3b protein fragments will 
deactivate when they rejoin with each other. Upon binding with a cellular membrane, C3b is 
binds to factor Ba and P, forming the alternative pathway C3-convertase (C3bBbP). A 
characteristic feature of the alternative pathway is a feedback mechanism that leads to 
accelerated C3 activation. Such mechanisms are not present in the classical pathway 
(Medicus et al., 1976; Rother et al., 1998). 
7.3.3 Mannose-binding lectin pathway 
A variant of the classical pathway, the Mannose-binding lectin pathway does not require 
antibodies. Activation of this pathway occurs when mannose-binding lectin (MBL) binds to 
mannose residues on the pathogen surface. Subsequently, the MBL complex can split C4 
and C2, generating  C3-convertase, as in the classical pathway (Petersen et al., 2001). This 
pathway will not be discussed further in this chapter. 
The convertases from both the classical and alternative pathways cleave C5 into C5a and 
C5b. The C5b molecule associates with C6, C7, C8, and C9, forming the C5b-9 membrane 
attack complex (MAC), which is inserted into the cell membrane and initiates cell lysis. The 
C5b-9, also called the terminal complement complex (TCC), may exist as a soluble active 
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form denoted sC5b-9. This soluble form can be measured to assess complement activation .  
The C5a and C3a fragments are anaphylatoxins that participate in the recruitment of 
inflammatory cells and trigger mast cell degranulation. Therefore, these anaphylatoxins 
participate in many forms of acute and chronic inflammation including sepsis (Guo et al., 
2004; Ward, 2008). 
7.3.4 Complement activation 
Extracorporal treatments such as haemodialysis and cardiopulmonary bypass activate the 
CS. Contact between blood and biomaterials may generate degradation fragments of 
complement C3a and C5a and soluble C5b-9. These fragments result in chemotaxis of 
leukocytes, cytokine release and generation of prostaglandins, resulting in a life-threatening 
condition termed “whole body” inflammation. Biomaterial induced CS is activated by both 
the classical and alternative pathways (Nilsson et al., 2007).  
The Chandler-Loop system was also used to assess CS activation. The complement 
activation parameters (C3a and C5b-9) were much higher for BC compared with the other 
materials, for both 4 and 6 mm tubes. Cellulose is known to induce complement activation 
in hemodialysis membranes (Frank et al., 2001). The mechanisms underlying these results 
for BC are still unclear and require further investigation. Bacterial fragments could still be 
present in the material. However, endotoxin values are well within the limit for 
cardiovascular devices. It is also possible that exposed hydroxyl groups induce 
complement activation through the alternative pathway (Arima et al., 2009; Toda et al., 
2008). The physiological significance in vivo of this complement activation remains 
undetermined. Interestingly, platelet activation is low even when complement activation 
is high. According to the literature, platelet consumption and complement activation are 
closely related (Fushimi et al., 1998; Hamad et al., 2008; Peerschke et al., 2006; 
Gyongyossy-Issa et al., 1994). 
8. What are the future therapeutic possibilities? 
This chapter has presented possible approaches to modifying BC that enhance EC growth in 
vitro. The XG method, an easy one-step procedure carried out in water, is an elegant 
technique for modifying BC to promote EC. Its advantage is the preservation of the fibre 
structure, thus maintaining its strength. The modification of BC with the XG technique is far 
from limited to the RGD peptide. Different peptide sequences or other active groups and 
growth factors could be attached to the XG molecule. Platelets could potentially adhere to 
exposed RGD peptides. Therefore, other peptides, more specific to ECs, or different 
combinations of peptides should be explored. 
Measurements of thrombin generation correlated well with the XIIa generation assay and 
visualisation of the propagation of coagulation. Together, these methods could offer 
potential fast screening methods for evaluating the thrombogenicity of biomaterials and 
future surface modifications. 
BC could be used for vascular grafts in two different approaches: (i) implantation as a 
tube without cells or (ii) seeding prior to implantation. The ideal BC modification would 
provide an initial nonthrombogenic surface and promote long-term endothelialisation. 
Future modifications of BC could include heparinisation or combinations of surface 
modifications, e.g., different peptides or coatings. Heparin is a potent antithrombotic 
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agent that functions by binding antithrombin. In recent years, heparinised ePTFE grafts 
(Propaten®) have been developed (Losel-Sadee & Alefelder, 2009). Although encouraging 
outcomes for below-knee bypass are reported, the compliance mismatch of ePTFE grafts 
still remains. However, this is an exciting modification and preliminary studies on 
heparinised BC tubes show considerably lower amounts of thrombin on the hep-BC 
surface. 
Our studies show that modification of BC with the adhesion-promoting peptide RGD results 
in increased EC adhesion, metabolism and spreading. Furthermore, BC induces slower 
coagulation than clinically available materials such as Gore-Tex® and Dacron® and induces 
the least contact activation as evaluated by Factor XIIa generation. In addition, BC consumes 
low quantities of platelets and generates low thrombin values as compared with Dacron® 
and Gore-Tex®.  
9. Conclusion 
Our work demonstrates that it is possible to introduce an adhesion peptide to BC that 
enhances EC adhesion without altering the fibre network or mechanical properties. The anti-
thrombogenic properties of BC, especially 4 mm tubes, are promising as compared with 
conventional graft materials. Therefore, BC emerges as a promising, novel vascular graft 
material for small-caliber grafts. Molecular studies confirm that BC exhibits low 
thrombogenicity and extensive EC adhesion, which are beneficial when introducing 
artificial materials in vivo during by-pass surgery. Together with the modification methods 
presented in this chapter, BC has the potential to become a material for artificial vessels, 
thus underlining the importance of increasing molecular understanding of EC and BC 
interactions to create novel opportunities for artificial blood vessels.  
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